Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVER HIV reservoir eradication trial
2014-001425-32Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raltegravir, vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv in human immunodeficiency virus infection (HIV) and Seroconversion Syndrome (2 arms), sponsored by Imperial College London. Status: unknown.
02
Drugs
raltegravirvorinostatChAdV63.HIVconsvMVA.HIVconsv
03
Conditions
human immunodeficiency virus infection (HIV)Seroconversion Syndrome
Beyond the preview
Go deeper on 2014-001425-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001425-32.